[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"renal-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:renal-tumor":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,71,96,122],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100343091","sabr-for-renal-tumors-100343091",false,"NCT03747133","SABR for Renal Tumors","Phase II Study: Stereotactic Ablative Radiotherapy for Renal Tumors","Inclusion Criteria:\n\n* Solid Kidney Mass (primary RCC or metastasis) amenable to SABR ≤6cm\n* Histological or radiological diagnosis of renal tumor\n* Inoperable: High risk for surgery or declined surgery\n* ECOG performance status of 0-3\n\nExclusion Criteria:\n\n* ≥5 active metastases\n* Systemic therapy (except endocrine therapy) within 60 days prior to SABR\n* Prior abdominal radiotherapy with fields overlap resulting in excessive doses to the involved kidney\n* Patients with end stage renal failure \\> 4(KDOQI guidelines)\n* Familial Syndrome: Von Hippel-Lindau disease, Polycystic Kidney Disease, Hereditary Papillary RCC or Tuber Sclerosis","ALL","18 Years",{"count":19,"type":20},90,"ESTIMATED","INTERVENTIONAL",[23],"NA","Renal Cell Carcinoma (RCC) is the most common type of kidney cancer. The usual treatment for this type of cancer is surgery. Considering the most common patients are an average age of 65 and some are not suitable candiates for surgery, there is great interest in non-surgical alternatives for kidney cancer treatments. This study will investigate the use of Stereotactic Ablative Radiosurgery (SABR) for renal tumors. SABR is a non-invasive alternative, which involves delivery of high doses of radiation to the target, while minimizing the risk of injury to the surrounding organs. Patients will be seen before and end of treatmetn and will be followed at 4 month intervals for up to 2 years. During the follow ups, patients will be asked to complete a quality of life questionnaire and will have standard of care imaging.",[26],"Renal Tumor",[28,29,30,31,32],"Stereotactic Body Radiation Therapy","SABR","Radiation Therapy","Renal Cell Carcinoma","RCC","RECRUITING","2026-06-03",{"date":36,"type":37},"2026-06-04","ACTUAL",{"date":39,"type":37},"2018-11-01",{"date":41,"type":20},"2027-11",{"name":43,"class":44},"University Health Network, Toronto","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":45},"100347967","early-phase-1-pencil-beam-scanning-in-patients-with-renal-tumors-100347967","NCT03810651","Pencil Beam Scanning in Patients With Renal Tumors","Pilot Study of Pencil Beam Scanning Proton Beam Radiation Therapy in Patients With Renal Tumors","Inclusion Criteria:\n\n* Less than 30 years of age\n* Diagnosis\n\n  a. Any patient with Wilms tumor or clear cell sarcoma of the kidney who would require radiation therapy as standard of care including\n  1. Any patient with favorable histology (FH), stage III disease\n  2. Any patient with focal or diffuse anaplasia\n  3. Any patient with CCSK\n* The patient is a candidate for external beam radiotherapy based on standard of care for treatment of Wilms tumor or CCSK\n\nExclusion Criteria:\n\n* Prior radiotherapy to the region of the study cancer\n* Chemotherapy administered for diagnosis of Wilms tumor or CCSK\n* Pregnant or breastfeeding","0 Years","30 Years",{"count":56,"type":20},28,[58],"EARLY_PHASE1","This is a pilot study to assess acute toxicity in patients receiving flank irradiation using proton therapy for renal tumors.",[26,61],"Wilms Tumor","2026-04-13",{"date":64,"type":37},"2026-04-15",{"date":66,"type":37},"2017-12-26",{"date":68,"type":20},"2028-10-30",{"name":70,"class":44},"Children's Hospital of Philadelphia",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":45},"100521972","petmr-for-characterization-of-renal-masses-rms-100521972","NCT06076538","PET\u002FMR for Characterization of Renal Masses (RMs)","Prospective Observational Study Using PET\u002FMR for Characterization of Renal Masses (RMs)","Inclusion Criteria:\n\n* Patients with known solid (\\>25% total volume enhances) renal mass\n* Renal mass size measuring \\>2 to ≤7 cm\n* Age \\>18 years\n* Ability to understand and the willingness to sign a written informed consent.\n\nExclusion Criteria:\n\n* Pregnancy\n* Prior percutaneous biopsy of the renal mass\n* Prior treatment of the renal mass\n* Prior hemorrhage in the renal mass\n* Contraindication to MRI or PET\n* Renal mass not eligible for ccLS based on prior imaging (i.e., containing macroscopic fat \\[classic angiomyolipoma\\] or enhancing less than 25% of its volume \\[considered a cystic renal mass\\])\n* Genetic syndrome predisposing to renal masses (e.g., VHL, BHD, TSC, etc.);\n* More than 3 renal masses at time of initial diagnosis",{"count":79,"type":20},97,"OBSERVATIONAL","The frequency of kidney tumors found incidentally on imaging studies performed for unrelated reasons continues to increase leading to more surgeries and ablations for the treatment of renal masses thought to be cancer. However, about 20% of these masses are not cancerous and do not require treatment. Many cancerous kidney tumors are indolent and can be followed safely with imaging (i.e., particularly tumors \\\u003C2 cm and in patients with limited life expectancy), while some tumors are both malignant and aggressive, with a higher potential to spread outside the kidney and require treatment.\n\nThe purpose of this observational study is to assess the ability of Fludeoxyglucose (18F) (FDG) PET\u002FMR to distinguish different types of kidney tumors. The investigators hypothesize that PET\u002FMR will better show differences between aggressive and both indolent and benign kidney masses compared to the currently used radiologic scans.\n\nParticipants will be selected from those who have been scheduled to receive a contrast-enhanced MRI for their regular care due to a suspicious kidney mass. Participants will have their MRI on a hybrid PET\u002FMR scanner capable of obtaining both MRI and PET images. While they are receiving their standard of care MRI exam, patients will also receive a research FDG PET exam. Participants will have an IV placed for administration of the MRI contrast agent, just as they would if they were not taking part in the study. The same IV will be used to give the FDG radiopharmaceutical for the PET scan and furosemide (a diuretic), to help empty the bladder before the scan and help better see the kidneys on the scans. Both FDG and furosemide are FDA approved medications. Participants will have only one visit with the research team which will last \\~2.5 hours and will include collection of the participant's regularly scheduled MRI.\n\nIf participants undergo surgery to remove the tumor, the study will collect samples of the removed tissue for research. If participants receive a biopsy of the tumor, the study may collect an additional sample of the tumor for research.\n\nAfter the PET\u002FMRI, participants will not have additional visits with the study team, but the study team may call every 6-12 months for up to 2 years to see how they are doing and ask about their health. The study team will review the medical record for any changes to their diagnosis, updates to their medical history, new scans ordered by their regular doctor, or recent lab or biopsy results.",[26,31,83],"Renal Tumor, Benign",[85,31,86],"Renal Mass","PET\u002FMR","2025-12-19",{"date":89,"type":37},"2025-12-29",{"date":91,"type":37},"2023-08-01",{"date":93,"type":20},"2028-06-01",{"name":95,"class":44},"University of Texas Southwestern Medical Center",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":21,"phases":105,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":119,"locationsCount":121},"100483221","a-ccafu-uroccr-randomized-trial-3d-image-guided-robot-assisted-partial-nephrectomy-for-renal-complex-tumor-uroccr-n99-100483221","NCT05572216","A CCafU-UroCCR Randomized Trial: 3D Image-Guided Robot-AssisTEd Partial Nephrectomy for Renal Complex Tumor (UroCCR N°99)","ACCURATE","Inclusion Criteria:\n\n* Patients over 18 years\n* Indication of RAPN for suspicious renal tumor\n* Moderate or high complexity renal tumor (RENAL Nephrometry Score (NS) \\>7)\n* Da Vinci® surgical system available for the surgery\n* Patient affiliated to the French social security system or an equivalent system\n* Signed informed consent form UroCCR and ACCURATE\n\nExclusion Criteria:\n\n* Medical contraindication to RAPN\n* Renal insufficiency forbidding iodine injection\n* Patient with allergy to iodinated contrast products\n* Patient concerned by articles L1121-5 to 8 of the French public health code (protected persons)",{"count":104,"type":20},694,[23],"The goal of this clinical trial is to evaluate peri and post-operative outcomes as well as long-term survival of 3D IGRAPN compared to conventional Robot-Assisted Partial Nephrectomy (RAPN) for moderate and highly complex renal tumors.\n\nThe main questions aim to answer:\n\n* peri-operative complications\n* oncological safety\n* long term renal function Participants will be asked to do undergo 3D-IGRAPN. Researchers will compare 3D-IGRAPN to RAPN to see if peri-operative outcomes are better in the experimental group.",[26,108],"Renal Cancer",[110,111,112],"image guidance","augmented reality","robotics","2024-11-14",{"date":115,"type":37},"2024-11-18",{"date":117,"type":37},"2023-01-24",{"date":41,"type":20},{"name":120,"class":44},"University Hospital, Grenoble",2,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":21,"phases":131,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":45},"100560081","robot-assisted-laparoscopic-partial-nephrectomy-via-the-extraperitoneal-approach-in-the-prone-position-versus-the-lateral-position-100560081","NCT06572501","Robot-assisted Laparoscopic Partial Nephrectomy Via the Extraperitoneal Approach in the Prone Position Versus the Lateral Position","Robot-assisted Laparoscopic Partial Nephrectomy Via the Extraperitoneal Approach in the Prone Position Versus the Lateral position-a Study Protocol for a Single-centre, Prospective, Randomised Controlled Trial","Inclusion Criteria:\n\n1. . Patients with preoperative imaging suggestive of renal occupancy;\n2. . Sex is not limited;\n3. . Age ≥18 years;\n4. . Clinical staging consistent with indications for partial nephrectomy;\n5. . Suitable for robotic-assisted laparoscopic partial nephrectomy via extraperitoneal approach as judged by relevant preoperative clinical data;\n6. . Agree to provide basic clinical information and pathological and imaging data for scientific research and sign an informed consent form;\n7. . Agree to provide monitoring results during the follow-up recurrence monitoring process.\n\nExclusion Criteria:\n\n1. . Patients who did not meet the indications for partial nephrectomy and did not undergo robotic-assisted laparoscopic partial nephrectomy via extraperitoneal approach;\n2. . Patients who refuse to undergo or cannot tolerate surgery in the appropriate position;\n3. . Patients with incomplete documentation of relevant data to provide accurate demographic, perioperative, and prognostic data;\n4. . Any condition which, in the opinion of the investigator, may be detrimental to the subject or result in the inability of the subject to meet or perform the requirements of the study;\n5. . Patients who are unable to provide written informed consent;",{"count":130,"type":20},200,[23],"The goal of this clinical trial is to investigate whether robot-assisted laparoscopic partial nephrectomy by extraperitoneal approach in the prone position had any advantages over the traditional lateral position. The main questions it aims to answer are:\n\nIs prone surgery safe and feasible, and what are the advantages over the traditional lateral position? Does surgery in the prone position have an impact on the patients\\' prognosis? Researchers will compare prone position to lateral position to see if robot-assisted laparoscopic partial nephrectomy by extraperitoneal approach in the prone position has any advantages over the traditional lateral position and whether it has any significant effect on the prognosis of the patients.\n\nParticipants will be randomly allocated 1:1 to two groups: prone position group and lateral position group. The enrolled patients will be underwent robotic-assisted laparoscopic partial nephrectomy via extraperitoneal approach according to the corresponding positions of their groups. Demographic indicators and perioperative-related indicators will be counted and recorded. CT or MRI and related biochemical examinations will be reviewed at 1 month, 3 months, 6 months and 1 year after surgery, and every 1 year thereafter. The similarities and differences of the indicators in different positions will be analysed, and subgroup analyses will be performed according to the corresponding results.",[26,134,135],"Prone Position","Robotic Assisted Partial Nephrectomy","2024-08-26",{"date":138,"type":37},"2024-08-27",{"date":140,"type":37},"2023-08-06",{"date":142,"type":20},"2030-01",{"name":144,"class":44},"The First Affiliated Hospital with Nanjing Medical University"]